AsurDx™ Burkholderia Mallei Antibody Test Kit
The AsurDx™ Burkholderia Mallei Antibody Test Kit is designed for the detection of antibodies specific to Burkholderia Mallei (B. mallei) in horse.
Feature
- Detects antibodies of the IgG in serum/plasma;
- Procedures last less than 90 minutes;
- Provides a simple, rapid, sensitive and cost-effective enzyme-based immunoassay (ELISA) screening method
*Availability/Distribution: Product is designed and developed by BioStone US Texas headquarter and manufactured/assembled by BioStone oversea subsidiaries or partners. Currently, the product is only available outside of the USA. Regulatory requirements vary by oversea countries; the product may not be available in your geographic area.
Specification
| Method | Competitive ELISA |
| Coated Antigen | B. mallei antigen-coated Plate |
| Incubation Time | 90 minutes |
| Storage | At least 12 months |
| Specificity | B. mallei serogroup-specific antibodies in horse serum/plasma |
Order Information
| Catalog Number | 10013-02 | 10013-05 |
| Plates | 2 plates | 5 plates |
| Reactions | 192 | 480 |
| Plate Format | 12 X 8-well strips | 12 X 8-well strips |
About Disease
Infection with the bacterium B. mallei can cause Glanders, an infectious disease that occurs primarily in horses, mules, and donkeys. Signs of glanders include the formation of nodular lesions in the lungs and ulceration of the mucous membranes in the upper respiratory tract. The acute form results in coughing, fever, and the release of an infectious nasal discharge, followed by septicaemia and death within days. In the chronic form, nasal and subcutaneous nodules develop, eventually ulcerating. Death can occur within months, while survivors act as carriers. Glanders is endemic in Africa, Asia, the Middle East, and Central and South America. It has been eradicated from North America, Australia, and most of Europe through surveillance and destruction of affected animals, and import restrictions. B. mallei is able to infect humans, so is classed as a zoonotic agent.